胃癌切除术后肿瘤表观遗传特征与生存的关系
本研究基于TCGA中270例接受R0或R1切除的胃腺癌患者,筛选与总生存相关的microRNA表观遗传特征。通过交叉验证识别出14个miRNA组成的预后panel,该panel在调整病理预后因素后仍与OS显著相关;panel预测生存低于上三分位切点的患者3年OS更差(30% vs 74%,p<0.0001)。
要点
- 在胃癌切除患者中,14个miRNA组成的表观遗传特征与总生存独立相关。
- 该特征在调整淋巴结检出数、阳性淋巴结数、TNM分期等后仍显著。
- panel预测生存低于上三分位切点者3年OS为30%,高于切点者为74%。
核心结论
- 在手术切除的胃腺癌患者中,一个与生存相关的miRNA表观遗传特征有潜力改善预后判断。
研究设计与样本
- 研究纳入TCGA中接受R0或R1切除、有临床特征、总生存和肿瘤miRNA表达数据的胃腺癌患者270例。
- 仅分析在至少15%肿瘤中表达的miRNA,从10个重复样本(每个含80%患者)中用年龄校正的比例风险回归逐步选择miRNA。
- 经多个重复样本交叉验证选出的miRNA,若能用全部患者优化总生存的加速失效时间模型则保留。
主要发现
- 在270例胃癌队列中,筛选的1870个miRNA中有916个符合评估标准。
- 交叉验证识别出20个预后miRNA,其中14个(miR-129-1、miR-373、miR-490、miR-597、miR-1185-2、miR-3943、miR-4756、miR-5683、miR-6510、miR-6733、miR-6808、miR-6855、miR-6882、miR-8072)具有独立信息。
- 年龄校正的14-miRNA panel在调整病理预后因素(淋巴结检出数、阳性淋巴结数)及其他临床协变量(TNM分期、残留肿瘤、肿瘤微卫星不稳定性、靶向分子治疗、性别、种族、民族)后仍与总生存显著相关。
- panel预测生存低于上三分位切点的患者预后更差,3年总生存为30% vs 74%(p<0.0001)。
临床怎么用
- 该14-miRNA表观遗传特征可作为胃癌切除术后预后评估的候选生物标志物,辅助识别高危患者。
- panel预测生存低于上三分位切点提示预后不良,或可指导术后随访和治疗强度决策。
局限性
- 研究基于TCGA公共队列,样本量270例,需外部独立队列验证。
- miRNA panel的临床效用和可重复性尚未在前瞻性研究中确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Precision oncology can identify patient-specific molecular signatures to better inform the prognosis and management of surgical cancer patients. Specifically, microRNAs (miRs) hold promise as prognostic biomarkers because dysregulation of individual miRs is implicated in tumorigenesis, progression, and metastases of various malignancies, including gastric adenocarcinoma (GC). STUDY DESIGN: To identify miRs prognostic of survival after radical gastrectomy, we studied GC patients within The Cancer Genome Atlas (TCGA) who had undergone R0 or R1 resection and had data on clinical characteristics, overall survival (OS), and tumor miR expression. The miRs expressed by at least 15% of tumors were eligible for study. From 10 replicate samples, each with 80% of patients, miRs were selected using age-adjusted proportional hazards regression with stepwise selection. Cross-validated miRs (selected by multiple replicates) were retained if they optimized an accelerated failure-time model of OS using all patients. RESULTS: In this GC cohort (n = 270), half (916/1,870) of miRs screened met our criteria for evaluation. Cross-validation identified 20 miRs as prognostic, of which 14 (miR-129-1, miR-373, miR-490, miR-597, miR-1185-2, miR-3943, miR-4756, miR-5683, miR-6510, miR-6733, miR-6808, miR-6855, miR-6882, miR-8072) were independently informative. The age-adjusted 14-miRNA panel remained significantly associated with OS after adjustment for pathologic prognostic factors (number of lymph nodes examined, number of positive lymph nodes) and other clinical covariates (TNM stage, residual tumor, tumor microsatellite instability, targeted molecular therapy, sex, race, ethnicity). Panel-predicted survival estimates below the upper tertile cut-off were associated with worse outcome (30% vs 74% OS at 3 years, p < 0.0001). CONCLUSIONS: In surgically resected GC patients, an epigenetic signature of miRs associated with survival has the potential to improve prognostication.
引用
- Woo Y, Behrendt CE, Yang A, et al. Tumor Epigenetic Signature and Survival in Resected Gastric Cancer Patients. J Am Coll Surg. 2021. PMID: 33465468. doi:10.1016/j.jamcollsurg.2020.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。